Vortioxetine
- Generic Name
- Vortioxetine
- Brand Names
- Brintellix, Trintellix
- Drug Type
- Small Molecule
- Chemical Formula
- C18H22N2S
- CAS Number
- 508233-74-7
- Unique Ingredient Identifier
- 3O2K1S3WQV
- Background
Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.
- Indication
用于治疗重度抑郁症成人患者。
- Associated Conditions
- Major Depressive Disorder (MDD)
Tolerability, Safety and Efficacy of Vortioxetine
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- IRCCS San Raffaele Roma
- Target Recruit Count
- 20
- Registration Number
- NCT04301492
- Locations
- 🇮🇹
IRCCS San Raffaele, Roma, Italy
🇮🇹IRCCS San Raffaele Roma, Rome, Italy
Vortioxetine in Patients With Depression and Early Dementia
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 82
- Registration Number
- NCT04294654
- Locations
- 🇫🇷
Centre de Recherche-Hopital Geriatrique de Charpennes, Villeurbanne, France
🇪🇪Marienthali Kliinik, Tallinn, Estonia
🇮🇹Azienda Ospedaliera di Perugia - Policlinico Monteluce, Perugia, Umbria, Italy
Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 400
- Registration Number
- NCT04288895
- Locations
- 🇮🇳
Vinaya Hospital & Research Centre (IN1007), Mangalore, Karnataka, India
🇮🇳BJ Medical College and Civil Hospital (IN028), Ahmedabad, Gujarat, India
🇮🇳Mangala Hospital & Mangala Kidney Foundation (IN1006), Mangalore, Karnataka, India
Vortioxetine for Cancer Patients With Depression: An Observational Study
- Conditions
- Major Depressive DisorderCancer
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- University of Malaya
- Target Recruit Count
- 140
- Registration Number
- NCT04253678
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
🇲🇾Hospital Raja Permaisuri Bainun, Ipoh, Ipoh, Perak, Malaysia
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 100
- Registration Number
- NCT04220996
- Locations
- 🇵🇱
Niepubliczny Zaklad Opieki Psychiatrycznej Mentis (PL0004), Leszno, Poland
🇵🇱Centrum Medyczne Luxmed Sp.Z O.O. (PL0006), Lublin, Poland
🇵🇱Clinical Research Center Spolka z ograniczona odpowiedzialnoscia Medic-R Sp.k. (PL0007), Poznan, Poland
Vortioxetine for the Treatment of Hoarding Disorder
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Noam Soreni
- Registration Number
- NCT04035850
- Locations
- 🇨🇦
St Joseph Healthcare, Hamilton, Ontario, Canada
Vortioxetine vs Sertraline in Mexicans
- Conditions
- Type 2 Diabetes MellitusDepression
- Interventions
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Universidad Juárez Autónoma de Tabasco
- Target Recruit Count
- 21
- Registration Number
- NCT03978286
A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 16
- Registration Number
- NCT03884491
- Locations
- 🇬🇧
Quotient Sciences Ltd, Nottingham, United Kingdom
Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Registration Number
- NCT03855865
Study With Vortioxetine on Emotional Functioning in Patients With Depression
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 150
- Registration Number
- NCT03835715
- Locations
- 🇫🇷
Cabinet Psyche (FR0012), Douai, France
🇱🇹JSC Romuvos Klinika (LT0002), Kaunas, Lithuania
🇪🇸University of Oviedo (ES0011), Oviedo, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.